文献速递皮肤肿瘤

接受全身抗肿瘤治疗患者的皮肤外科围手术期管理

Perioperative management of dermatologic surgery patients on systemic cancer therapy.
PubMed 文献 · J Am Acad Dermatol · 2026-07-01

本文综述了三级癌症中心中接受靶向治疗、细胞毒化疗、免疫调节剂、蛋白酶体抑制剂及抗体药物偶联物等全身抗肿瘤治疗患者的皮肤外科围手术期管理策略,整合FDA处方信息、已发表数据及多学科专家建议,强调个体化决策、术前实验室评估、对已知影响伤口愈合或血液学药物谨慎中断用药时机及术后密切监测。

要点

  • 个体化决策是核心,需平衡伤口愈合、出血、感染风险与肿瘤进展及治疗中断的后果。
  • 对已知影响伤口愈合或血液学的药物,应术前评估实验室并谨慎选择中断时机。
  • 术后需密切监测,建议皮肤外科与肿瘤科多学科协作管理。

核心结论

  • 全身抗肿瘤治疗患者的皮肤外科围手术期管理应基于个体化决策、术前实验室评估、谨慎中断用药时机和术后密切监测。

研究设计与样本

  • 本文为综述,整合FDA处方信息、已发表数据及Mohs外科医生与肿瘤内科医生多学科会议形成的专家建议。

主要发现

  • 靶向治疗、细胞毒化疗、免疫调节剂、蛋白酶体抑制剂和抗体药物偶联物等各类药物在围手术期各有不同考虑。
  • 免疫治疗和靶向治疗的快速扩展使更多接受全身抗肿瘤治疗的患者需行皮肤外科手术。

临床怎么用

  • 皮肤外科医生与肿瘤科医生应多学科协作,对接受全身抗肿瘤治疗的患者制定个体化围手术期方案。
  • 术前进行实验室评估,对已知影响伤口愈合或血液学的药物谨慎安排中断时机,术后密切监测。

局限性

  • 推荐基于专家建议和已发表数据,非随机对照研究证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rapid expansion of immunotherapy and targeted oncologic treatments leading to improved overall survival has led to a growing number of patients requiring dermatologic surgery for skin cancer while receiving systemic cancer therapy. However, perioperative management in this setting remains poorly defined. Dermatologic surgeons and oncologists must balance risks of impaired wound healing, bleeding, and infection against potential consequences of skin cancer progression versus treatment interruption, underscoring the need for multidisciplinary guidance. Here, we review perioperative management strategies at a tertiary cancer center and integrate FDA prescribing information, published data, and expert recommendations developed through multidisciplinary meetings between Mohs surgeons and medical oncologists. Our recommendations address key therapeutic classes including targeted therapies, cytotoxic chemotherapies, immunomodulators, proteosome inhibitors, and antibody drug conjugates, each of which presents distinct considerations. Across therapies, optimal management centers on individualized decision-making, preoperative laboratory assessment, careful timing of drug interruption for agents with known wound-healing or hematologic effects, and close postoperative monitoring. As systemic therapies continue to evolve, these expert-based recommendations aim to support safe, personalized perioperative care for the increasing population of oncology patients undergoing dermatologic surgery.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Trager MH, Gordon ER, Handfield C, et al. Perioperative management of dermatologic surgery patients on systemic cancer therapy. J Am Acad Dermatol. 2026. PMID: 42385893. doi:10.1016/j.jaad.2026.06.126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。